Brief: Vasomune Therapeutics, Inc., And Anges, Inc., Announce Us FDA Clearance Of Investigational New Drug (Ind) Application For Pegevongitide (Av-001) Treatment In Resuscitation Of Severely Burned Patients
04/03/2026 12:56
March 4 (Reuters) - AnGes Inc 4563.T: VASOMUNE THERAPEUTICS, INC., AND ANGES, INC., ANNOUNCE US FDA CLEARANCE OF INVESTIGATIONAL NEW DRUG (IND) APPLICATION FOR PEGEVONGITIDE (AV-001) TREATMENT IN RESUSCITATION OF SEVERELY BURNED PATIENTS Source text: ID:nBw3rHf49a Further company coverage: 4563.T ((Reuters.Briefs@thomsonreuters.com;))
Recent news on AnGes
See all newsTable: Anges -Q1 group results
Brief: Vasomune Therapeutics, Inc., And Anges, Inc., Announce Us FDA Clearance Of Investigational New Drug (Ind) Application For Pegevongitide (Av-001) Treatment In Resuscitation Of Severely Burned Patients
Table: Anges -2025 parent results
Table: Anges -2025 group results
Brief: Anges & Vasomune Therapeutics Enter Agreement For AV-001